β-Carboline analogues have shown activity against Alzheimer’s disease (AD) through various mechanisms, including cholinesterase and monoamine oxidase (MAO) inhibition, anti-inflammatory activity and anti-Aβ accumulation activity [121,122,123,124,125]. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.